Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 9, 1997, Pages 1687-1690

  Ridker, Paul M ^a   Baker, Michael T ^d   Hennekens, Charles H ^a,b,c   Stampfer, Meir J ^a   Vaughan, Douglas E ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

Genetics; Myocardial infarction; Plasminogen activators; Risk factors; Thrombosis

Indexed keywords

DNA; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ALU SEQUENCE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

AGING; ALLELES; COHORT STUDIES; DNA TRANSPOSABLE ELEMENTS; GENE DELETION; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; REPETITIVE SEQUENCES, NUCLEIC ACID; RISK FACTORS; SMOKING; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030768313     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
2. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
3. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long term mortality in patients with coronary artery disease: a seven year follow-up. Circulation. 1993;88:2030-2034.
4. Thompson SG, Kienast J, Pyke SDM, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
5. Tishkoff SA, Ruano G, Kidd JR, Kidd KK. Distribution and frequency of a polymorphic Alu insertion at the plasminogen activator locus in humans. Hum Genet. 1996;97:759-764.
6. Ludwig M, Wohn KD, Schleuning WD, Olek K. Allelic dimorphism in the human tissue-type plasminogen (TPA) gene as a result of an Alu insertion/deletion event. Hum Genet. 1992;88:388-392.
7. van der Bom JG, Bots ML, Haverkate F, Grobbee DE, Kluft C. Fibrinolytic capacity and risk of myocardial infarction. Fibrinofysis. 1996;10(suppl 2):9-12.
8. van der Bom JG, de Knijff P, Bots ML, Haverkate F, Hofman A, Kluft C, Grobbee DE. Polymorphism of the blood clot lysis enzyme tissue type plasminogen activator is associated with myocardial infarction. Circulation. 1995;92(suppl 2):1-30.
9. Iacoviello L, Di Casstelnuovo A, de Knijff P, D'Orazio A, Amore C, Kluft C, Donati MB. Alu-repeat polymorphism in the tissue-type plasminogen activator (t-PA) gene, t-PA levels and risk of familial myocardial infarction (MI). Fibrinofysis. 1996;10(suppl 2),13-16.
10. Hennekens CH, Buring JE. Epidemiology in Medicine. Boston, MA: Little, Brown, and Co., 1987.
11. Steering Committee of the Physicians' Health Study Research Group. Final report of the aspirin component of the ongoing Physicians' Health Study. NEngl J Med. 1989;321:129-135.
12. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995; 332:912-917.
13. Humphries S. The genetic contribution to the risk of thrombosis and cardiovascular disease. Trends Cardiovasc Med. 1994;4:8-17.
14. Van den Eijnden-Schrauwen Y, Lakenberg N, Emeis JJ, de Knijff P. Alu-repeat polymorphism in the tissue-type plasminogen activator (t-PA) gene does not affect basal endothelial t-PA synthesis. Thromb Haemost. 1995;74:1202.
15. Hamsten A, Wiman B, DeFaire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313: 1557-1563.
16. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG, on behalf of the ECAT Study Group. Fibrinolytic factors and the risk of myocardial infarction or sudden death inpatients with angina pectoris. Circulation. 1996;94:2057-2063.
17. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischemie, heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-37.
18. Meade TW, Ruddock V, Stirling Y, Charkrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-79.
19. Lijnen HR, Collen D. Impaired fibrinolysis and the risk of coronary heart disease. Circulation. 1996;94:2052-2054.
20. Ridker FM. Plasma concentration of endogenous tissue plasminogen activator and the occurrence of future cardiovascular events. Thromb Thrombol. 1994;1:35-40.
21. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation. 1997;95:59-62.
22. Meilahn EN, Kuller LH, Mathews KA, Kiss JE. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol. 1992;2:445-455.
23. Scarabin PY, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost. 1993; 70:584-587.
24. Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, Wu KK. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostasis factors in moderately overweight adults. Arterioscler Thromb. 1993;13:162-169.
25. Ridker PM, Vaughan DE, Stampfer MJ, Hennekens CH. Association of moderate alcohol consumption and plasma concentration of endogenous tissue plasminogen activator. JAMA. 1994;272: 929-933.
26. Lee AJ, Flanagan A, Rumley A, Fowkes FGR, Lowe GDO. Relationship between alcohol intake and tissue plasminogen activator antigen and other haemostatic factors in the general population. Fibrinolysis. 1995;8:49-54.
27. Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in the II diabetic patients. Diabetes. 1993; 42:1-7.
28. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabctohgia. 1991;34:457-462.
29. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation. 1989;79:101-106.
30. Andreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int. 1991;8:336-351.